- Q4 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 07, 2024€0.98 (-0.51%)Earnings
- Q3 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 09, 2023€1.01 (-3.81%)Earnings
- Q2 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 10, 2023€1.27Earnings
- Q1 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 11, 2023€1.31Earnings
- Q4 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 09, 2023€1.34 (+3.68%)Earnings
- Q3 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 10, 2022€1.26 (+5.29%)Earnings
- Q2 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 11, 2022€1.5 (+4.50%)Earnings
- Q1 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 12, 2022€1.17 (-0.21%)Earnings
- Lineage Cell Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 27, 2022
- Lineage Cell Therapeutics Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 20, 2022
- Q4 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 10, 2022€1.21 (+0.83%)Earnings
- Lineage Cell Therapeutics Inc To Discuss Worldwide OpRegen Collaboration Call TranscriptDec 20, 2021
- Q3 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 10, 2021€2.1 (-1.87%)Earnings
- Lineage Cell Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas (Virtual) TranscriptOct 18, 2021
- Q2 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 12, 2021€2.24 (+2.75%)Earnings
- Lineage Cell Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Lineage Cell Therapeutics Inc Webinar Featuring External Therapeutic Area Experts TranscriptJun 10, 2021
- Q1 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 13, 2021€1.92 (-1.03%)Earnings
- Q4 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 11, 2021€1.84 (-0.54%)Earnings
- Lineage Cell Therapeutics Inc Corporate Analyst Meeting TranscriptFeb 22, 2021
- Lineage Cell Therapeutics, Inc. - Special Call TranscriptNov 17, 2020
- Q3 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 04, 2020€1.03 (+10.75%)Earnings
- Q2 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 06, 2020€0.82 (+13.89%)Earnings
- Lineage Cell Therapeutics, Inc. - Special Call TranscriptJun 08, 2020
- Lineage Cell Therapeutics, Inc. - Special Call TranscriptMay 11, 2020
- Q1 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 07, 2020€0.91 (-3.19%)Earnings
- Q4 2019 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 12, 2020€0.66 (-7.04%)Earnings
- Lineage Cell Therapeutics Inc at Solebury Trout KOL Day TranscriptNov 15, 2019
- Q3 2019 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 12, 2019€0.65 (-10.96%)Earnings
- Q2 2019 BioTime Inc Earnings Call TranscriptAug 08, 2019€0.85 (-1.16%)Earnings
- Q1 2019 BioTime Inc Earnings Call TranscriptMay 09, 2019€1.07Earnings
- Q4 2018 BioTime Inc Earnings Call TranscriptMar 14, 2019€1.42 (+2.16%)Earnings
Lineage Cell Therapeutics Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
All right. Well, thank you, everyone. I appreciate Noble giving me the opportunity to conclude today's sessions; I will aim to make this one very memorable for you. Speaking of memorable, I know all of us in this room are old enough to remember, let's say, 20 years ago, when there was a lot of excitement about something called cell therapy, and it promised all sorts of wonderful and amazing things, new medicines, et cetera, et cetera. There were many scientists that were touting this new era; I was one of them, in fact. And I've got good news and bad news.
The bad news, of course, is that 20 years have gone by, and, with the exception of cancer, cell therapy hasn't really produced a lot of the things that it was promising to produce. However, the good news is it's finally starting to happen. And you can measure this in certain ways. You can measure this in the development of products, but you can also measure it on the capital side. And because this is an investment conference, you can point to things like the $1 billion acquisition of BlueRock
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)